HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients

Authors:

Abstract
Brain metastases from colorectal cancer (CRC) are a rare but increasing event as patients survive longer. While HER2 gene amplification in breast cancer is well described and known to increase risk of brain metastases [1], information in CRC patients with brain metastases is lacking. A multi-centre phase II trial has shown that HER2-directed therapies are efficacious in HER2 positive (HER2+) stage IV CRC without brain metastases [2]. If HER2 is enriched in CRC patients with brain metastases, it may provide a possible therapeutic target.
Funding Information
  • National Cancer Centre Singapore Research Fund